hotspot -WSS

hotspot

author：knowledge 2025-09-06 03:53:03 - browse：5

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Boston's new lab space is opening empty

hotspot

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

As AI in medicine takes off, can 'human in the loop' prevent harm?

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Liquid biopsy for lung cancer is launched by Delfi

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

hotspot

hotspot

knowledge

Activists slam private health insurers over coverage restrictions

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Sports medicine is finally prioritizing gender equality

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In age of alternative facts, a scholarly course on calling out crap

Pushing for an NIH office for post

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

The cancer drug shortage isn’t new — and neither are the solutions

John Green on his newest strategy for fighting tuberculosis

focus

Change Healthcare outage fallout shows need for new oversight

UCLA team creates talking throat patch for voice disorders

Why Charlie Gard's case is so disturbing to Americans

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Physician executives need more than on

Why age limits for politicians are a terrible idea

hotspot

focus

hotspot

hotspot